Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
I'm not trying to be negative but a properly researched insight into an investment in Avacta would have already illuminated all these possibilities and much much more. Don't worry - there will be significant new news this week then there will be plenty for real investors to discuss other than as you put it brochuregate. Sometimes it is so hard to see the wood for the sleaze but pretty soon all the negativity and nonsense of the last 18 months will be history - the crew will move on somewhere else and those of us who have researched and understand the potential will just kick back and count our millions.
Good luck all true investors
Ophidian
@Muck165 - I wasn't but it applies equally as well. Try this one from 2018
https://pubmed.ncbi.nlm.nih.gov/30545831/
Ophidian
Timster - it depends what you want to call manufacturing........ refer to the ABDX latest update and take away the number of devices they say they can make from the number of "strips" they are making (or have capacity to make).
Medusa have purchased kit to assemble cassettes - my guess is ABDX will make the strips so they are the manufacturer and Med19 will assemble LFD's and market them as Meduflow.
Ophidian
@Monkshood - there are multiple papers detailing where the linker in use in AVA6000 accumulates in the body in mouse and primate models. The specific Toxicity issues associated with Doxorubicin are primarily Heart then Liver & Kidneys. Only for alcoholics with advanced Liver Cirrhosis might this be a problem. This is not a forum for debating science in great detail so it is not reasonable to use pseudo science as a blanket for masking nefarious intent. Guff seems pretty reasonable to me. As a scientist you should also be able to differentiate the intriguing but irrelevant from the critical. Refocusing extraordinarily gifted minds to this reality was a significant part of my job - seems very few are capable of doing it for themselves beyond a certain point.
Ophidian
By way of a parting example......
The profile of how and where the therapeutic accumulates throughout the body will be different for the proDrug vs the unmodified version.
[Yes it will - except how or where the inert prodoxorubicin accumulates has zero bearing on toxicity effects that are important. Once it is cleaved - the doxorubicin that was once bound by the linker within the AVA6000 is absolutely no different to doxorubicin that may have been dosed as normal - it doesn't know and even if it did it can't behave differently chemistry and biology don't make choices based on brands. - so utterly pointless guff]
Human bodies aren’t mice, so how/where it will accumulate in humans is unknown and any side effects are yet to be established.
[Simply not true - there are multiple studies which have reported precisely where in the body these things accumulate (plasma mostly for Humans by the way) also our resident (non)-eggspurt forgets to mention that his free FAP(a) theory is flawed by the simple truth that Mice have 10-15 times more free FAP circulating than Humans do. ]
This is the point of the phased trials. To discover efficacy vs side effects.
[so painfully naive I'm not even going to waste time typing]
We are currently establishing the MTD to then investigate therapeutic effects in later phases of the trial
[even a broken clock is right twice a day]
Most investors aren’t oncologists, so we have to make an educated guess how this will play out.
[Yes - investors make their own guesses - some would call them informed judgements - either way they do not require your continual tedious Janet and John Wiki-Science butchery]
I’m totally content to maintain my shareholding and not indulge brainless ramps and/or the pseudo-knowledge of quacks
There is so much guff written on here by people with clearly little of no scientific knowledge nor familiarity with the pharmaceutical industry / clinical trials process. We have been told it's a 3 + 3 design following a modified Fibonacci design - I suggest if you don't know what that means you go find out rather then rely on being told by "helpful" contributors. (Also check out what "pivotal" means for a clinical trial)
Similarly - there is so much information in the public domain about FAP(a) and it's role in Cancers / prodrugs I suggest you go do some proper learning.
The real risk with AVA6000 entering the clinic wasn't that it wouldn't work in humans in respect of FAP(a) cleaving the linker to release doxorubicin in the environment of the Tumour - that was already a given proven in preclinical studies by Avacta and multiple times by the collaborating Universities Chemistry and Biology don't make choices - they follow rules. The risk was that the linker might, like so many other failed efforts, be cleaved by another similar looking enzyme.
So much complete gonads has been spouted on here about FAP(a) being practically everywhere around the Human body just waiting to hijack the AVA6000 - again utter rubbish. Most recently we had the fantasy that Zero doxorubicin was needed outside the Tumour site to expect any sort of success. There are some great papers I suggest you go read - I particularly like the Mouse / Baboon / Human one it is full of useful details.
Even a well deserved ban seemingly does not deter some from continuing to spam and lie and insult. Just like a couple of posts mirroring what has been Tweeted in more words convince the unwary that the contributor has nothing but honourable intent - Ho Hum...... I've previously tried to answer question and debunk the nonsense and share information I glean and insights I have. That gets me little but abuse - so good luck everyone with your investments and I very strongly urge you to do your own more than just skimming research and arm yourselves against the barrage of nonsense that continues to plague this board. I'll be on Twitter again for a while
Ophidian
oh Mart - still living up to your name I see. When you posted "maybe the EU should have gone to his lordship for their data." I assume you are being rude and referring to me - in which case I can tell you very happily that on many occasions they did. I have drafted several of the current EU (and US as it happens) guidelines. I also said "from experience", I didn't quote a guidance document.
Keep trying